Nov. 28, 2022

A Tricyclic, Atropisomeric BTK Inhibitor from Janssen

JNJ-64264681

oral BTK inhibitor Ph. I candidate in NHL/CLL patients from Janssen cmp. collection screen and opt. J. Med. Chem. Janssen, San Diego, CA

twitterlinkedinprintemail